Nanobiotix (NASDAQ:NBTX) Stock Price Up 8.9% – Here’s What Happened

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) traded up 8.9% on Wednesday . The company traded as high as $34.18 and last traded at $33.6150. 6,247 shares traded hands during trading, a decline of 86% from the average session volume of 44,243 shares. The stock had previously closed at $30.87.

Analyst Upgrades and Downgrades

Several research analysts have commented on NBTX shares. TD Cowen reissued a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research note on Thursday, January 22nd. Finally, Guggenheim increased their target price on shares of Nanobiotix from $8.00 to $26.00 and gave the company a “buy” rating in a report on Friday, February 6th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Nanobiotix Trading Up 12.1%

The firm has a 50-day moving average of $27.62 and a 200-day moving average of $23.12.

Nanobiotix (NASDAQ:NBTX) last released its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The firm had revenue of $3.42 million during the quarter. On average, analysts predict that Nanobiotix S.A. – Sponsored ADR will post -1.18 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Millennium Management LLC purchased a new stake in Nanobiotix in the 4th quarter worth approximately $390,000. Marshall Wace LLP bought a new stake in shares of Nanobiotix in the 4th quarter worth approximately $220,000. Optiver Holding B.V. purchased a new position in shares of Nanobiotix during the third quarter valued at approximately $101,000. Finally, Royal Bank of Canada raised its holdings in shares of Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after acquiring an additional 2,500 shares in the last quarter. Institutional investors own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.